Literature DB >> 21550186

Mitogen-activated protein kinases p38 and JNK mediate Actinobacillus pleuropneumoniae exotoxin ApxI-induced apoptosis in porcine alveolar macrophages.

Chi-Ming Wu1, Zeng-Weng Chen, Ter-Hsin Chen, Jiunn-Wang Liao, Cheng-Chung Lin, Maw-Sheng Chien, Wei-Cheng Lee, Shih-Ling Hsuan.   

Abstract

Actinobacillus pleuropneumoniae exotoxins (Apx) are major virulence factors that play important roles in the pathogenesis of pleuropneumonia in swine. A previous study has demonstrated that native ApxI at low concentrations induces apoptosis in primary porcine alveolar macrophages (PAMs) via a caspase-3-dependent pathway. However, the molecular mechanisms underlying ApxI-induced apoptosis remain largely unknown. In this study, it was shown that ApxI treatment in PAMs rapidly induced phosphorylation of both p38 and JNK, members of the mitogen-activated protein kinase family. Application of a selective p38 or JNK inhibitor significantly reduced ApxI-induced apoptosis, indicating the involvement of p38 and JNK pathways in this event. Furthermore, activation of both caspase-8 and -9 were observed in ApxI-stimulated PAMs. Inhibition of caspase-8 and caspase-9 activity significantly protected PAMs from ApxI-induced apoptosis. In addition, Bid activation was also noted in ApxI-treated PAMs, and inhibition of caspase-8 suppressed the activation of Bid and caspase-9, suggesting that ApxI was able to activate the caspases-8-Bid-caspase-9 pathway. Notably, inhibition of p38 or JNK pathway greatly attenuated the activation of caspases-3, -8, and -9. This study is the first to demonstrate that ApxI-induced apoptosis of PAMs involves the activation of p38 and JNK, and engages the extrinsic and intrinsic apoptotic pathways.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550186     DOI: 10.1016/j.vetmic.2011.03.033

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

1.  Mig-2 attenuates cisplatin-induced apoptosis of human glioma cells in vitro through AKT/JNK and AKT/p38 signaling pathways.

Authors:  Yun-wei Ou; Zi-tong Zhao; Chuan-yue Wu; Bai-nan Xu; Yong-mei Song; Qi-min Zhan
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

2.  Elucidating the role of ApxI in hemolysis and cellular damage by using a novel apxIA mutant of Actinobacillus pleuropneumoniae serotype 10.

Authors:  Nai-Yun Chang; Zeng-Weng Chen; Ter-Hsin Chen; Jiunn-Wang Liao; Cheng-Chung Lin; Maw-Sheng Chien; Wei-Cheng Lee; Jiunn-Horng Lin; Shih-Ling Hsuan
Journal:  J Vet Sci       Date:  2013-06-30       Impact factor: 1.672

3.  Effective Pro-Inflammatory Induced Activity of GALT, a Conserved Antigen in A. Pleuropneumoniae, Improves the Cytokines Secretion of Macrophage via p38, ERK1/2 and JNK MAPKs Signal Pathway.

Authors:  Fei Zhang; Qin Zhao; Jin Tian; Yung-Fu Chang; Xintian Wen; Xiaobo Huang; Rui Wu; Yiping Wen; Qigui Yan; Yong Huang; Xiaoping Ma; Xinfeng Han; Chang Miao; Sanjie Cao
Journal:  Front Cell Infect Microbiol       Date:  2018-09-25       Impact factor: 5.293

4.  Global Gene Networks in 3D4/31 Porcine Alveolar Macrophages Treated with Antigenic Epitopes of Actinobacillus pleuropneumoniae ApxIA, IIA, and IVA.

Authors:  Suji Kim; Myung Whan Oh; Woo Bin Park; Han Sang Yoo
Journal:  Sci Rep       Date:  2019-03-27       Impact factor: 4.379

5.  An in vitro study of ApxI from Actinobacillus pleuropneumoniae serotype 10 and induction of NLRP3 inflammasome-dependent cell death.

Authors:  Eduardo Hernandez-Cuellar; Alma Lilián Guerrero-Barrera; Francisco Javier Avelar-Gonzalez; Juan Manuel Díaz; Jesús Chávez-Reyes; Alfredo Salazar de Santiago
Journal:  Vet Rec Open       Date:  2021-10-04

6.  Actinobacillus pleuropneumoniae induces SJPL cell cycle arrest in G2/M-phase and inhibits porcine reproductive and respiratory syndrome virus replication.

Authors:  Jérémy A Ferreira Barbosa; Josée Labrie; Francis Beaudry; Carl A Gagnon; Mario Jacques
Journal:  Virol J       Date:  2015-11-14       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.